PBAC's latest decision on Belantamab mafodotin: Recommended with restriction (2025). Considered for Relapsed and/or refractory multiple myeloma (RRMM) after one prior line of therapy, in combination with bortezomib and dexamethasone.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Redacted
commercial-in-confidence
Submissions
1
first 2025
Submissions
1
2025 → 2025
Eligible population
Adults with relapsed or refractory multiple myeloma who have received one prior line of therapy, treated with belantamab mafodotin 2.5 mg/kg intravenously every 3 weeks in combination with bortezomib and dexamethasone.
Therapy area
Oncology
Line of therapy
Second-line
Evidence base
RCT
Primary endpoint
PFS
Key trials
DREAMM-7
Comparator
daratumumab in combination with bortezomib and dexamethasone (DBd)
Economic model
CEA
ICER note
ICER value redacted (shown as '****' in the submission); economic analysis performed but commercially sensitive.